Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

Herbert J. Zeh, David L. Bartlett

Research output: Contribution to journalReview article

81 Citations (Scopus)

Abstract

Tumor directed gene therapy for the purpose of destroying cancer cells through replicative "oncolysis" or by intratumoral expression of toxic or immunostimulatory genes requires an efficient, tumor targeted vector. Vectors are limited by inefficient replication in vivo, inefficient tumor targeting, and safety concerns. As a unique approach to addressing these limitations, our laboratory has studied poxviruses as tumor selective replicating vectors. The best in vivo antitumor results achieved to date have been with a mutated WR strain of vaccinia virus. The unique advantage of this strain of vaccinia over other vectors currently being explored for this purpose is the efficiency of in vivo replication. Intradermal injection of 106 pfu of the wild type (non-mutated) vaccinia in non-human primates leads to a 108 cm2 zone of necrosis in 8 days - directly related to cellular destruction from viral replication. We have mutated the virus through insertional deletion of both the thymidine kinase (TK) gene and vaccinia growth factor (VGF) gene. The mutant virus no longer causes destruction of normal tissue, but has completely preserved replication efficiency in tumor tissue and can safely be delivered systematically to successfully treat subcutaneous tumors in mice. Plans are now underway for clinical trials.

Original languageEnglish (US)
Pages (from-to)1001-1012
Number of pages12
JournalCancer Gene Therapy
Volume9
Issue number12
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Poxviridae
Neoplasms
Vaccinia
Therapeutics
Genes
Viruses
Intradermal Injections
Thymidine Kinase
Vaccinia virus
Poisons
Genetic Therapy
Primates
Necrosis
Clinical Trials
Safety

Keywords

  • Cancer
  • Gene therapy
  • Replicating
  • Vaccinia
  • Vector

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. / Zeh, Herbert J.; Bartlett, David L.

In: Cancer Gene Therapy, Vol. 9, No. 12, 01.12.2002, p. 1001-1012.

Research output: Contribution to journalReview article

@article{e51634b3abf94660949a06972d5c5031,
title = "Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers",
abstract = "Tumor directed gene therapy for the purpose of destroying cancer cells through replicative {"}oncolysis{"} or by intratumoral expression of toxic or immunostimulatory genes requires an efficient, tumor targeted vector. Vectors are limited by inefficient replication in vivo, inefficient tumor targeting, and safety concerns. As a unique approach to addressing these limitations, our laboratory has studied poxviruses as tumor selective replicating vectors. The best in vivo antitumor results achieved to date have been with a mutated WR strain of vaccinia virus. The unique advantage of this strain of vaccinia over other vectors currently being explored for this purpose is the efficiency of in vivo replication. Intradermal injection of 106 pfu of the wild type (non-mutated) vaccinia in non-human primates leads to a 108 cm2 zone of necrosis in 8 days - directly related to cellular destruction from viral replication. We have mutated the virus through insertional deletion of both the thymidine kinase (TK) gene and vaccinia growth factor (VGF) gene. The mutant virus no longer causes destruction of normal tissue, but has completely preserved replication efficiency in tumor tissue and can safely be delivered systematically to successfully treat subcutaneous tumors in mice. Plans are now underway for clinical trials.",
keywords = "Cancer, Gene therapy, Replicating, Vaccinia, Vector",
author = "Zeh, {Herbert J.} and Bartlett, {David L.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1038/sj.cgt.7700549",
language = "English (US)",
volume = "9",
pages = "1001--1012",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

AU - Zeh, Herbert J.

AU - Bartlett, David L.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Tumor directed gene therapy for the purpose of destroying cancer cells through replicative "oncolysis" or by intratumoral expression of toxic or immunostimulatory genes requires an efficient, tumor targeted vector. Vectors are limited by inefficient replication in vivo, inefficient tumor targeting, and safety concerns. As a unique approach to addressing these limitations, our laboratory has studied poxviruses as tumor selective replicating vectors. The best in vivo antitumor results achieved to date have been with a mutated WR strain of vaccinia virus. The unique advantage of this strain of vaccinia over other vectors currently being explored for this purpose is the efficiency of in vivo replication. Intradermal injection of 106 pfu of the wild type (non-mutated) vaccinia in non-human primates leads to a 108 cm2 zone of necrosis in 8 days - directly related to cellular destruction from viral replication. We have mutated the virus through insertional deletion of both the thymidine kinase (TK) gene and vaccinia growth factor (VGF) gene. The mutant virus no longer causes destruction of normal tissue, but has completely preserved replication efficiency in tumor tissue and can safely be delivered systematically to successfully treat subcutaneous tumors in mice. Plans are now underway for clinical trials.

AB - Tumor directed gene therapy for the purpose of destroying cancer cells through replicative "oncolysis" or by intratumoral expression of toxic or immunostimulatory genes requires an efficient, tumor targeted vector. Vectors are limited by inefficient replication in vivo, inefficient tumor targeting, and safety concerns. As a unique approach to addressing these limitations, our laboratory has studied poxviruses as tumor selective replicating vectors. The best in vivo antitumor results achieved to date have been with a mutated WR strain of vaccinia virus. The unique advantage of this strain of vaccinia over other vectors currently being explored for this purpose is the efficiency of in vivo replication. Intradermal injection of 106 pfu of the wild type (non-mutated) vaccinia in non-human primates leads to a 108 cm2 zone of necrosis in 8 days - directly related to cellular destruction from viral replication. We have mutated the virus through insertional deletion of both the thymidine kinase (TK) gene and vaccinia growth factor (VGF) gene. The mutant virus no longer causes destruction of normal tissue, but has completely preserved replication efficiency in tumor tissue and can safely be delivered systematically to successfully treat subcutaneous tumors in mice. Plans are now underway for clinical trials.

KW - Cancer

KW - Gene therapy

KW - Replicating

KW - Vaccinia

KW - Vector

UR - http://www.scopus.com/inward/record.url?scp=0036905081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036905081&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700549

DO - 10.1038/sj.cgt.7700549

M3 - Review article

C2 - 12522439

AN - SCOPUS:0036905081

VL - 9

SP - 1001

EP - 1012

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 12

ER -